As a rule of thumb, children should receive the primary series of four doses of IPV when they are 2 months old. However, if they are not fully vaccinated, they should receive the second and third doses four weeks apart. Boostrix-IPV and Adacel Polio are given only as booster doses and are only recommended for children under age four. In addition, vaccines should be given at least six months before the child's first birthday.
Vaccines
for the prevention of polio have become more widely available. There are two
types of IPV vaccines: inactivated IPV and live-virus vaccine. The former is
given subcutaneously while the latter is given intramuscularly. Vaccines for
both are given in combination with diphtheria-tetanus-pertussis. While there
are some precautionary recommendations regarding the safety of these two
vaccines, the overall safety of IPV vaccination is not at risk. The IPV
vaccines market report caters to various stakeholders in this industry
including investors, suppliers
CDC
recommended Pediarix for infants of mothers with HBsAg or who were not sure of
their status. In addition to the CDC, the FDA approves Pentacel for the first
four doses of component vaccine in children six weeks through four years.
Adults should not receive a primary series of polio vaccine unless they are
travelling to an area with wild-type virus. However, adults should get a
booster dose if they plan on visiting an area where wild-type virus is
prevalent.
In
developing countries, IPV is a relatively new vaccine that offers lifelong
protection against the disease. The two vaccines differ mainly in their ability
to stop the transmission of live poliovirus. In countries with an OPV program,
trivalent OPV was used in routine immunization activities. Trivalent IPV is
available only in the trivalent form. Developed countries are expected to
continue using IPV in the future. Lower-income countries, however, are likely
to prefer OPV. And countries without external financial support may prefer to
use fractional doses instead of a full-dose vaccine. That would mean
significant savings for them and less demand for IPV manufacturers.